Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

Findings suggest that 17-AAG biological effects in KIT-positive GISTs result mainly from KIT oncoprotein inhibition, and suggests that HSP90 inhibition provides a therapeutic solution to the challenge of heterogeneous imatinib resistance mutations in GIST patients.